Neurodegenerative diseases include Motor Neurone Disease (MND), Alzheimer’s and Parkinson’s. MND is a progressive degenerative disorder of motor neurones that leads to muscle weakness and death. Neurones are nerve cells that carry information as tiny electrical signals. Researchers at Lancaster University in the UK are engaged in conducting a new trial to test the diabetes drug Liraglutide in people with MND. In a previous study, these same researchers discovered that Liraglutide can help patients with Alzheimer’s. The researchers believe that because neurodegenerative diseases are a “family” of diseases, if a new treatment can be found for one, it may prove useful for others too. There is a sound basis fror this expectation. As a diabetes drug, Liraglutide controls the release of insulin by binding to specific protein receptive sites in the pancreas. These same receptive sites also are found in the brain where they participate in maintaining the metabolic health of neurones. Activation of these protein receptive sites in the brain with drugs such as Liraglutide might therefore work to protect neurones from damage. Read more here.